Radnor Capital Management LLC Sells 2,200 Shares of Boston Scientific Co. (NYSE:BSX)

Radnor Capital Management LLC cut its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 36.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,852 shares of the medical equipment provider’s stock after selling 2,200 shares during the quarter. Radnor Capital Management LLC’s holdings in Boston Scientific were worth $344,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Global Wealth Strategies & Associates increased its holdings in shares of Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 250 shares during the period. West Oak Capital LLC bought a new position in shares of Boston Scientific during the fourth quarter worth approximately $29,000. Dunhill Financial LLC increased its holdings in shares of Boston Scientific by 86.4% during the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 152 shares during the period. Values First Advisors Inc. bought a new position in shares of Boston Scientific during the third quarter worth approximately $28,000. Finally, E Fund Management Hong Kong Co. Ltd. bought a new position in shares of Boston Scientific during the third quarter worth approximately $30,000. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the transaction, the executive vice president now owns 29,308 shares of the company’s stock, valued at $2,660,580.24. This trade represents a 19.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 14,010 shares of Boston Scientific stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the sale, the executive vice president now directly owns 978 shares of the company’s stock, valued at approximately $87,306.06. This trade represents a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,989 shares of company stock valued at $2,702,261 over the last quarter. Insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $96.87 on Thursday. The company has a fifty day moving average price of $90.36 and a 200-day moving average price of $84.15. The company has a market capitalization of $142.77 billion, a P/E ratio of 80.06, a PEG ratio of 2.67 and a beta of 0.80. Boston Scientific Co. has a 52-week low of $59.61 and a 52-week high of $97.36. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The business had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter last year, the firm earned $0.50 earnings per share. Boston Scientific’s quarterly revenue was up 19.3% on a year-over-year basis. As a group, equities analysts expect that Boston Scientific Co. will post 2.46 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on BSX shares. Needham & Company LLC reiterated a “hold” rating on shares of Boston Scientific in a research report on Wednesday, November 27th. Mizuho increased their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. Citigroup increased their price target on shares of Boston Scientific from $98.00 to $107.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Wells Fargo & Company increased their price target on shares of Boston Scientific from $98.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Finally, StockNews.com lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Three equities research analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $97.26.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.